Crossmark

T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: preclinical evaluation and mechanisms, prediction, and exploration of adverse effects

Crossref DOI link: https://doi.org/10.1007/s12672-025-02239-2

Published Online: 2025-05-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wan, Guangmin

Yang, Lu

Wang, Quan

Xu, Gang
Funding

Funding for this research was provided by:

National Cancer Center Climbing Program (NCC201916B01)
License Information

Text and Data Mining valid from 2025-05-22

Version of Record valid from 2025-05-22
More Information

Article History

Received: 17 January 2025

Accepted: 25 March 2025

First Online: 22 May 2025

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below